The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2007Restrain FGF20 by miRNA: Lowering the Risk to Parkinson's Disease
Objective/Rationale:
The variations in FGF20 gene play important roles in developing Parkinson’s disease. Recently, we found such a genetic variation in FGF20 gene strongly associated with PD. That... -
Rapid Response Innovation Awards, 2007Engineered Drug Receptors as a Parkinson's Disease Therapy
Objective/Rationale:
The purpose of this project is to determine whether insertion of an engineered drug receptor into the subthalamic nucleus of a parkinsonian rat can alleviate akinesia when the... -
Rapid Response Innovation Awards, 2007Differentiation of Human Amniotic Fluid Stem Cells for Potential Use in Parkinson's Disease
Objective/Rationale:
Cell replacement remains one of the most promising approaches to treat Parkinson’s, particularly at late stages of the disease. Legal, ethical and pragmatic concerns have become... -
Rapid Response Innovation Awards, 2007LRRK2-mediated Axonal Dysfunction
Objective/Rationale:
The Parkinson’s disease-linked Leucine Rich Repeat Kinase 2 (LRRK2) gene causes changes in the length of processes extending from nerve cells especially the axons. Because changes... -
LEAPS, 2007Inosine for Parkinson's Disease: Safety and Trial Design Optimization
The Phase III trial is currently recruiting. Learn more: https://foxtrialfinder.michaeljfox.org/trial/4305/
Objective/Rationale:
Urate – a natural metabolite and major antioxidant in humans – is... -
Development of Progressive Pre-clinical Models of PD, 2006Generation of Transgenic Mice with Selective and Progressive Loss of Nigrostriatal Dopaminergic Neurons
Mutations in the alpha-synuclein gene are responsible for rare, dominantly inherited forms of familial Parkinson's disease, designated PARK1 and PARK4. Furthermore, alpha-synuclein is also the major...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.